GeneDx Q4 revenue $61.4M (+6.2% YoY), full-year net loss $667.6M; 2023 guidance reiterated

GeneDx Holdings Corp.

Combined revenue $61.4M in Q4 (+6.2% YoY); full year $234.7M (+10% YoY). Net operating loss $667.6M for FY22.
Pro forma continuing ops revenue $45.8M in Q4 (+32% YoY); full year $171.0M (+38% YoY). Adjusted gross margin 41% in Q4.
Completed $150M public offering in Jan 2023; cash position $138.3M at Dec 31, 2022.
Reiterated FY2023 guidance: revenue $205-220M, cash burn $130-145M, targeting profitability in 2025.
Whole exome sequencing volume grew 18.8% YoY in Q4; total volume up 25.8%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.